摘要【目的】探讨神经母细胞瘤(NB)的临床特点及影响NB患儿预后的相关因素。【方法】回顾性分析2019年1月至2022年9月本院收治的121例NB患儿的临床资料,单因素分析采用Kaplan Meier法统计各组患儿的平均生存时间,采用Log-rank检验分析各组患者生存时间差异,多因素分析采用Cox回归模型分析影响患儿生存时间的独立危险因素,分析NB临床因素与生存时间、生存结局的相关性。【结果】Log-rank检验分析显示,性别、乳酸脱氢酶(LDH)、NMYC基因扩增、核分裂指数、INSS分期、COG危险度分组、组织学类型是影响患儿生存时间的因素(P<0.05)。Cox回归模型多因素分析显示,LDH≥500 U/L、NMYC基因扩增及INSS分期4期是影响患儿生存预后的独立危险因素(P<0.05)。【结论】NMYC基因扩增及INSS分期4期是影响患儿预后的危险因素,检测血清LDH水平对评估 NB 患儿预后有重要意义。
Abstract：【Objective】To investigate the clinical characteristics and prognostic factors of neuroblastoma(NB) in children. 【Methods】A retrospective analysis was conducted on the clinical data of 121 children with NB admitted to our hospital from January 2019 to September 2022. The Kaplan Meier method was used for univariate analysis to calculate the average survival time of each group of patients,and the Log-rank test was used to analyze the differences in survival rate among groups. The Cox regression model was used for multivariate analysis to analyze the independent risk factors affecting the survival rate of children,and the correlation between NB clinical factors and survival time and outcome was analyzed. 【Results】Log-rank test analysis showed that gender,LDH,NMYC amplification,MKI index,INSS stage,COG risk group,and histological type were factors affecting the survival time of children(P<0.05). Multivariate analysis using the Cox regression model showed that LDH≥500 U/L,NMYC gene amplification,and INSS stage 4 were independent risk factors affecting the survival prognosis of children(P<0.05). 【Conclusion】NMYC amplification and INSS stage 4 are risk factors affecting the prognosis of children with NB;detecting serum LDH is of great significance for evaluating the prognosis of children with NB.
[1] 鲁冬芳,陈希,舒强.高危神经母细胞瘤分子遗传学特征研究进展[J].中华小儿外科杂志,2021,42(1):81-87. [2] CAPASSO M,DISKIN S J. Genetics and genomics of neuroblastoma[J].Cancer Treat Res,2010,155:65-84. [3] LIANG W H,FEDERICO S A,LONDON W B,et al.Tailoring therapy for children with neuroblastoma based on risk group classification:Past,present,and future[J].JCO Clin Cancer Inform,2020,4:895-905. [4] CAROLINE C,MERYLE J,JACQUELINE M,et al.Updates in diagnosis,management,and treatment of neuroblastoma[J].Radio Graphics,2018,38(2):566-580. [5] KIEUHOA T,KATHERINE K M,Neuhaus J,et al.Clinical,biologic,and prognostic differences on the basis of primary tumor site in neuroblastoma:a report from the international neuroblastoma risk group project[J].J Clin Oncol,2014 32(28):3169-3176. [6] 朱呈光,贺湘玲,汤止戈,等. 44例儿童神经母细胞瘤临床分析[J].中国当代儿科杂志,2020,22(11):1193-1197. [7] BROOKS G A. The science and translation of lactate shuttle theory[J].Cell Metab,2018,27(4) :757-785. [8] 丘金梅,龚娟,谢青池,等. 乳酸脱氢酶在肿瘤代谢中的作用及以其为靶标的抗肿瘤药物研发[J].肿瘤防治研究,2020,47(12):980-985. [9] 刘涛,盛庆丰,刘江斌,等.INSS 4期神经母细胞瘤患儿3年无事件生存率的相关因素分析[J].临床小儿外科杂志,2022,21(2):121-127. [10] OTTE J,DYBERG C,PEPICH A,et al. MYCN Function in neuroblastoma development[J].Front Oncol,2021,10:624079. [11] 杨震,李烨,张黄成昊.小儿神经母细胞瘤的预后及影响因素分析[J].中外医学研究,2021,19(10):56-58. [12] 王焕民.关于神经母细胞瘤外科治疗的几点思考[J].临床小儿外科杂志,2022,21(2):101-103. [13] 高建,薛明信,铁新琴,等.儿童神经母细胞瘤 36 例临床分析[J].中华实用儿科临床杂志,2019,34(6):453-456. [14] ANDERSON J,MAJZNER R G,SONDEL P M. Immunotherapy of neuroblastoma:facts and hopes[J].Clin Cancer Res,2022,28(15):3196-3206.
2023, Vol. 40 
